To register for the on demand webcast please login or create an account.
The recent results of apixaban in the CARAVAGGIO study in patients with cancer associated thrombosis, including patients with gastro-intestinal cancer with very high risk of gastro-intestinal bleeding, have triggered us to organize this webcast. Additionally we will discuss results of studies in different patient sets (non-cancer VTE and AF).
In this webcast, pertinent published data available on all DOACs versus comparators are presented by international key opinion leaders in the field of venous thromboembolism treatment and stroke prevention in atrial fibrillation. This webcast will give the audience insight into results of clinical trials as well as real world studies, emphasizing the clinical relevance of differences between DOACs, and how this may support in their choice of treatment.
- Treatment of VTE in patients with cancer
- Treatment and long-term secondary prevention of VTE
- Prevention of stroke in patients with AF
- Prof. dr. Giancarlo Agnelli, internist, University of Perugia, Italy
- Dr. Alexander Cohen, vascular physician and epidemiologist, Guy’s and St Thomas’ Hospital London, United Kingdom
- Prof. dr. Gregory Lip, cardiologist, University of Liverpool, UK and Aalborg University, Denmark
- Prof. dr. Menno Huisman, internist in cardiovascular medicine, LUMC Leiden, The Netherlands (moderator)
This webcast will be broadcast on Tuesday the 25th of May 2021 from 20.30 PM to 22.00 PM. The webcast will be in English.
This webcast is intended for cardiologists, internists, geriatric specialists, gastroenterologists, hematologists, pharmacists and general practitioners.
Participation in this webcast is free of charge.
If you have any questions, please send an email to firstname.lastname@example.org.
This webcast is sponsored by
432-NL-2100009 maart 2021
In the context of GDPR, Springer complies with the laws and regulations as laid down by this law. For this webcast it applies that it concerns a collaboration between Springer, Pfizer and BMS and that they each determine their own purpose and means in the processing of personal data. Springer, Pfizer and BMS are therefore separately responsible for processing. The privacy conditions that apply can be found here: Springer Healthcare, Pfizer & Bristol-Myers Squibb.